Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function

Stefanović,Nikola  Z.; Cvetković,Tatjana  P.; Jevtović‑Stoimenov,Tatjana  M.; Ignjatović,Aleksandra  M.; Paunović,Goran  J.; Veličković,Radmila  M.

doi:10.3892/etm.2015.2598

Investigation of CYP 3A5 and ABCB1 gene polymorphisms in the long-term following renal transplantation: Effects on tacrolimus exposure and kidney function

Authors:
- Nikola Z. Stefanović
- Tatjana P. Cvetković
- Tatjana M. Jevtović‑Stoimenov
- Aleksandra M. Ignjatović
- Goran J. Paunović
- Radmila M. Veličković
View Affiliations

Affiliations: Department of Pharmacy, Faculty of Medicine, University of Nis, Nis 18000, Serbia, Institute of Biochemistry, Faculty of Medicine, University of Nis, Nis 18000, Serbia, Department of Medical Statistics, Faculty of Medicine, University of Nis, Nis 18000, Serbia, Clinic of Nephrology, Clinical Centre Nis, Nis 18000, Serbia
Published online on: June 26, 2015 https://doi.org/10.3892/etm.2015.2598
Pages: 1149-1156

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The clinical use of tacrolimus (Tac) is complicated by the large inter-individual variability in its pharmacokinetics as well as by chronic adverse effects on renal function. The main goal of this study was to evaluate the potential influence of cytochrome P450 3A5 (CYP 3A5) and ATP‑binding cassette transporter B1 (ABCB1) gene polymorphisms on Tac dose requirements and dose‑adjusted concentrations in different long‑term periods following renal transplantation. Another aim was to investigate whether these polymorphisms affect renal function in late post‑transplant period. A total of 91 renal transplant recipients were enrolled for genotyping analysis, and 53 of these entered into a pharmacokinetic‑pharmacogenetic study. Allele‑specific polymerase chain reaction was used for CYP 3A5 and ABCB1 polymorphism determination. Pharmacokinetic data (dose, trough concentration and dose‑adjusted concentration of Tac) and renal function parameters [creatinine (Cre) clearance and serum Cre level] were analyzed in relation to patient genotype at 6, 12 and 24 months after transplantation. Also, linear regression analysis was performed to evaluate the effect of CYP 3A5 and ABCB1 genotypes on Tac exposure and renal function up to 24 months post‑transplant. Individuals carrying the CYP 3A5*1/*3 genotype had higher Tac dose requirements than CYP 3A5*3/*3 carriers at 6, 12 and 24 months after renal transplantation. The results revealed that ABCB1 polymorphism did not influence Tac dose requirements independently. Regression analysis showed that CYP 3A5 influenced the Tac dose‑adjusted concentration as well as renal function up to 24 months post‑transplant. These findings confirmed that CYP 3A5 polymorphism represents the most important determinant of Tac dose and exposure in the late period following renal transplantation. Furthermore, the obtained results indicate that the decline in renal function may be more pronounced in patients with CYP 3A5*1 in the long-term period after renal transplantation.

View Figures

View References

1	Press RR, de Fijter JW and Guchelaar HJ: Individualizing calcineurin inhibitor therapy in renal transplantation - current limitations and perspectives. Curr Pharm Des. 16:176–186. 2010. View Article : Google Scholar : PubMed/NCBI
2	Masuda S and Inui K: An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther. 112:184–198. 2006. View Article : Google Scholar : PubMed/NCBI
3	MacPhee IA: Pharmacogenetic biomarkers: Cytochrome P450 3A5. Clin Chim Acta. 413:1312–1317. 2012. View Article : Google Scholar : PubMed/NCBI
4	Velickovic-Radovanovic R, Mikov M, Catic-Djordjevic A, et al: Tacrolimus as a part of immunosuppressive treatment in kidney transplantation patients: Sex differences. Gend Med. 9:471–480. 2012. View Article : Google Scholar : PubMed/NCBI
5	Staatz CE, Goodman LK and Tett SE: Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet. 49:141–175. 2010. View Article : Google Scholar : PubMed/NCBI
6	Staatz CE, Goodman LK and Tett SE: Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet. 49:207–221. 2010. View Article : Google Scholar : PubMed/NCBI
7	Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K and Vanrenterghem Y: CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther. 82:711–725. 2007. View Article : Google Scholar : PubMed/NCBI
8	Hesselink DA, Bouamar R, Elens L, van Schaik RH and van Gelder T: The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 53:123–139. 2014. View Article : Google Scholar : PubMed/NCBI
9	Cusinato DA, Lacchini R, Romao EA, Moysés-Neto M and Coelho EB: Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients. Br J Clin Pharmacol. 78:364–372. 2014. View Article : Google Scholar : PubMed/NCBI
10	Kurzawski M, Dąbrowska J, Dziewanowski K, Domański L, Perużyńska M and Droździk M: CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients. Pharmacogenomics. 15:179–188. 2014. View Article : Google Scholar : PubMed/NCBI
11	Provenzani A, Notarbartolo M, Labbozzetta M, et al: Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med. 28:1093–1102. 2011.PubMed/NCBI
12	Ganji MR and Harririan A: Chronic allograft dysfunction: Major contributing factors. Iran J Kidney Dis. 6:88–93. 2012.PubMed/NCBI
13	Câmara NO, Williams WW Jr and Pacheco-Silva A: Proximal tubular dysfunction as an indicator of chronic graft dysfunction. Braz J Med Biol Res. 42:229–236. 2009. View Article : Google Scholar : PubMed/NCBI
14	Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N and Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 130:461–470. 1999. View Article : Google Scholar : PubMed/NCBI
15	Ashavaid TF, Raje HS, Shah BV and Shah SA: Design of allele specific PCR for rapid detection of CYP3A5 (A6986G) and Mdr-1 (C3435T) polymorphisms. Indian J Clin Biochem. 26:18–21. 2011. View Article : Google Scholar : PubMed/NCBI
16	Anglicheau D, Verstuyft C, Laurent-Puig P, et al: Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 14:1889–1896. 2003. View Article : Google Scholar : PubMed/NCBI
17	Larriba J, Imperiali N, Groppa R, Giordani C, Algranatti S and Redal MA: Pharmacogenetics of immunosuppressant polymorphism of CYP3A5 in renal transplant recipients. Transplant Proc. 42:257–259. 2010. View Article : Google Scholar : PubMed/NCBI
18	Lamba JK, Lin YS, Schuetz EG and Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 54:1271–1294. 2002. View Article : Google Scholar : PubMed/NCBI
19	Gervasini G, Vizcaino S, Gasiba C, Carrillo JA and Benitez J: Differences in CYP3A5* 3 genotype distribution and combinations with other polymorphisms between Spaniards and other Caucasian populations. Ther Drug Monit. 27:819–821. 2005. View Article : Google Scholar : PubMed/NCBI
20	Elmachad M, Elkabbaj D, Elkerch F, et al: Frequencies of CYP3A5* 1/* 3 variants in a Moroccan population and effect on tacrolimus daily dose requirements in renal transplant patients. Genet Test Mol Biomarkers. 16:644–647. 2012. View Article : Google Scholar : PubMed/NCBI
21	Ameyaw MM, Regateiro F, Li T, et al: MDR1 pharmacogenetics: Frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 11:217–221. 2001. View Article : Google Scholar : PubMed/NCBI
22	Rosso Felipe C, de Sandes TV, Sampaio EL, Park SI, Silva HT Jr and Medina Pestana JO: Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. Transplant Proc. 41:1441–1455. 2009. View Article : Google Scholar : PubMed/NCBI
23	Miao LY, Huang CR, Hou JQ and Qian MY: Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients. Biopharm Drug Dispos. 29:1–5. 2008. View Article : Google Scholar : PubMed/NCBI
24	Tada H, Tsuchiya N, Satoh S, et al: Impact of CYP3A5 and MDR1 (ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc. 37:1730–1732. 2005. View Article : Google Scholar : PubMed/NCBI
25	Nie XM, Gui R, Zhao HS, et al: Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients. J Cent South Univ Technol. 12:(Sul 1). S310–S313. 2005. View Article : Google Scholar
26	Zheng HX, Zeevi A, McCurry K, et al: The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol. 14:37–42. 2005. View Article : Google Scholar : PubMed/NCBI
27	Haufroid V, Mourad M, Van Kerckhove V, et al: The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 14:147–154. 2004. View Article : Google Scholar : PubMed/NCBI
28	López-Montenegro Soria MA, Kanter Berga J, Beltrán Catalán S, Milara Payá J, Pallardó Mateu LM and Jiménez Torres NV: Genetic polymorphisms and individualized tacrolimus dosing. Transplant Proc. 42:3031–3033. 2010. View Article : Google Scholar : PubMed/NCBI
29	Hesselink DA, van Schaik RH, van der Heiden IP, et al: Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 74:245–254. 2003. View Article : Google Scholar : PubMed/NCBI
30	Li Y, Hu X, Cai B, et al: Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Transpl Immunol. 27:12–18. 2012. View Article : Google Scholar : PubMed/NCBI
31	Glowacki F, Lionet A, Buob D, et al: CYP3A5 and ABCB1 polymorphisms in donor and recipient: Impact on tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transplant. 26:3046–3050. 2011. View Article : Google Scholar : PubMed/NCBI
32	Kuypers DR, Naesens M, de Jonge H, Lerut E, Verbeke K and Vanrenterghem Y: Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients. Ther Drug Monit. 32:394–404. 2010. View Article : Google Scholar : PubMed/NCBI
33	Naesens M, Kuypers DR and Sarwal M: Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 4:481–508. 2009.PubMed/NCBI